•
Jun 30, 2024
PDS Biotechnology Q2 2024 Earnings Report
PDS Biotech reported a net loss and provided a business update.
Key Takeaways
PDS Biotech reported a net loss of $8.3 million for Q2 2024, a decrease from the $11.5 million net loss in Q2 2023, driven by lower operating expenses. The company is preparing to initiate a Phase 3 trial in Q4 2024.
Aligned with FDA on Phase 3 trial design for Versamune® HPV + pembrolizumab in first-line recurrent/metastatic HPV16-positive HNSCC.
VERSATILE-003 Phase 3 trial statistical endpoints revised for robustness based on VERSATILE-002 trial results.
Updated data from VERSATILE-002 trial to be presented at ESMO Congress 2024.
Abstracts accepted for presentation at ESMO, ASTRO, and the International Cytokine and Interferon Society meetings.
PDS Biotechnology
PDS Biotechnology
Forward Guidance
PDS Biotech is planning to initiate the Phase 3 VERSATILE-003 trial in Q4 2024.